coffe_amd_link_thumbnail
June 23, 2025

Study Links Instant Coffee to Increased Risk of Age-Related Macular Degeneration

Quick caffeine fix, long-term AMD risk? This study serves up new grounds for concern. A splash of convenience may come…

SightByte InFocus Video #1 thumbnail
June 17, 2025

MICE TV SightByte In Focus: Private Equity – Profits Over Patient Care?

What happens when profit clashes with patient care?  In this first episode of MICE TV SightByte In Focus, we dive…

popular posts
[Newsroom] Thumbnail GLP1 and AMD Story
June 10, 2025

GLP-1 Agonists Associated with Doubled Risk of Neovascular AMD, Study Finds

coffe_amd_link_thumbnail
June 23, 2025

Study Links Instant Coffee to Increased Risk of Age-Related Macular Degeneration

latest posts
Untitled 1
August 20, 2024

Atsena Therapeutics Receives FDA RPD Designation for X-Linked Retinoschisis Gene Therapy Candidate

REGENERON 02
June 17, 2024

Regeneron Awarded Injunctions Blocking Eylea Biosimilars

Espansione Group’s eye light_V2 02
June 3, 2024

Espansione Group’s eye-light® Expands Its Horizons: New CE (MDR) Mark for Corneal and Retinal Care

FDA Approves First Two Aflibercept 2mg Biosimilars With Interchangeability
May 21, 2024

FDA Approves First Two Aflibercept 2mg Biosimilars With Interchangeability

Screen Shot 2023 10 03 at 9.13.51 PM
December 7, 2023

Back with a Roar!: The European VitreoRetinal Society is back after a three-year hiatus

DSC_0001 2
December 1, 2023

From COVID Challenges to Collective Progress: AOS-PAO 2023 Sets Sights on Global Trends and Regional Perspectives

COVER STORY ART
December 7, 2023

THE NOT-SO-SWEET LIFE: Trial and tribulations when navigating the bittersweet realities of diabetic retinopathy

COVER ART_500
August 17, 2023

Still the Gold Standard: Fifty years on, laser therapy remains a gold standard for some retinal treatment niches

Discover our fascinating content at issuu

explore